Registry for Patients With X-Linked Hypophosphatemia

计划入组 1,489 人 · 首次发布于 2017 年 6 月 20 日

Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)

计划入组 20 人 · 首次发布于 2014 年 12 月 9 日

Study of Longitudinal Observation for Patient With X-linked Hypophosphatemic Rickets/Osteomalacia in Collaboration With Asian Partners

计划入组 226 人 · 首次发布于 2018 年 11 月 19 日

cFGF23 gene therapy (AAV, X-linked hypophosphatemia)

fibroblast growth factor 23-C tail (X-linked hypophosphatemia)

Burosumab(Crysvita)

Rx

Molecule X LLC

Mexico

SFJ Pharmaceuticals X, LTD.

X-Pert-Med GmbH

Germany

FDA Approves Enhanced Dosing Options for CRYSVITA in Adults with X-linked Hypophosphatemia

FDA Grants Orphan Drug and Rare Pediatric Disease Designations to HKBU's Aptamer for X-Linked Hypophosphatemia

Recent Advances and Therapeutic Applications of FGF-based Drug Development